143 related articles for article (PubMed ID: 20074987)
1. Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase inhibitors in cancer therapy.
da Silva CH; da Silva VB; Resende J; Rodrigues PF; Bononi FC; Benevenuto CG; Taft CA
J Mol Graph Model; 2010 Feb; 28(6):513-23. PubMed ID: 20074987
[TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics, density functional, ADMET predictions, virtual screening, and molecular interaction field studies for identification and evaluation of novel potential CDK2 inhibitors in cancer therapy.
da Silva VB; Kawano DF; Gomes Ada S; Carvalho I; Taft CA; da Silva CH
J Phys Chem A; 2008 Sep; 112(38):8902-10. PubMed ID: 18698751
[TBL] [Abstract][Full Text] [Related]
3. Ligand-based virtual screening and in silico design of new antimalarial compounds using nonstochastic and stochastic total and atom-type quadratic maps.
Marrero-Ponce Y; Iyarreta-Veitía M; Montero-Torres A; Romero-Zaldivar C; Brandt CA; Avila PE; Kirchgatter K; Machado Y
J Chem Inf Model; 2005; 45(4):1082-100. PubMed ID: 16045304
[TBL] [Abstract][Full Text] [Related]
4. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
5. Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors.
Mizutani MY; Itai A
J Med Chem; 2004 Sep; 47(20):4818-28. PubMed ID: 15369385
[TBL] [Abstract][Full Text] [Related]
6. Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
Mitsch A; Bergemann S; Gust R; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2003 Jul; 336(4-5):242-50. PubMed ID: 12916059
[TBL] [Abstract][Full Text] [Related]
7. Farnesyltransferase inhibitors as anticancer agents: current status.
Zhu K; Hamilton AD; Sebti SM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
[TBL] [Abstract][Full Text] [Related]
8. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of piperidine farnesyltransferase inhibitors with reduced glucuronidation potential.
Tanaka R; Rubio A; Harn NK; Gernert D; Grese TA; Eishima J; Hara M; Yoda N; Ohashi R; Kuwabara T; Soga S; Akinaga S; Nara S; Kanda Y
Bioorg Med Chem; 2007 Feb; 15(3):1363-82. PubMed ID: 17127066
[TBL] [Abstract][Full Text] [Related]
10. Enzyme flexibility and the catalytic mechanism of farnesyltransferase: targeting the relation.
Sousa SF; Fernandes PA; Ramos MJ
J Phys Chem B; 2008 Jul; 112(29):8681-91. PubMed ID: 18572907
[TBL] [Abstract][Full Text] [Related]
11. In silico chemical library screening and experimental validation of a novel 9-aminoacridine based lead-inhibitor of human S-adenosylmethionine decarboxylase.
Brooks WH; McCloskey DE; Daniel KG; Ealick SE; Secrist JA; Waud WR; Pegg AE; Guida WC
J Chem Inf Model; 2007; 47(5):1897-905. PubMed ID: 17676832
[TBL] [Abstract][Full Text] [Related]
12. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid.
Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M
J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268
[TBL] [Abstract][Full Text] [Related]
13. 3D-QSAR with the aid of pharmacophore search and docking-based alignments for farnesyltransferase inhibitors.
Vaidya M; Weigt M; Wiese M
Eur J Med Chem; 2009 Oct; 44(10):4070-82. PubMed ID: 19515462
[TBL] [Abstract][Full Text] [Related]
14. Discovery and structure-activity relationships of novel piperidine inhibitors of farnesyltransferase.
Nara S; Tanaka R; Eishima J; Hara M; Takahashi Y; Otaki S; Foglesong RJ; Hughes PF; Turkington S; Kanda Y
J Med Chem; 2003 Jun; 46(12):2467-73. PubMed ID: 12773050
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design of imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase.
Ohkanda J; Strickland CL; Blaskovich MA; Carrico D; Lockman JW; Vogt A; Bucher CJ; Sun J; Qian Y; Knowles D; Pusateri EE; Sebti SM; Hamilton AD
Org Biomol Chem; 2006 Feb; 4(3):482-92. PubMed ID: 16446806
[TBL] [Abstract][Full Text] [Related]
16. "Inject-mix-react-separate-and-quantitate" (IMReSQ) method for screening enzyme inhibitors.
Wong E; Okhonin V; Berezovski MV; Nozaki T; Waldmann H; Alexandrov K; Krylov SN
J Am Chem Soc; 2008 Sep; 130(36):11862-3. PubMed ID: 18702487
[TBL] [Abstract][Full Text] [Related]
17. Solid-phase synthesis and pharmacological evaluation of a library of peptidomimetics as potential farnesyltransferase inhibitors: an approach to new lead compounds.
Gilleron P; Millet R; Houssin R; Wlodarczyk N; Farce A; Lemoine A; Goossens JF; Chavatte P; Pommery N; Hénichart JP
Eur J Med Chem; 2006 Jun; 41(6):745-55. PubMed ID: 16647166
[TBL] [Abstract][Full Text] [Related]
18. Development of benzophenone-based farnesyltransferase inhibitors as novel antimalarials.
Kohring K; Wiesner J; Altenkämper M; Sakowski J; Silber K; Hillebrecht A; Haebel P; Dahse HM; Ortmann R; Jomaa H; Klebe G; Schlitzer M
ChemMedChem; 2008 Aug; 3(8):1217-31. PubMed ID: 18470859
[TBL] [Abstract][Full Text] [Related]
19. Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation.
Kuck D; Singh N; Lyko F; Medina-Franco JL
Bioorg Med Chem; 2010 Jan; 18(2):822-9. PubMed ID: 20006515
[TBL] [Abstract][Full Text] [Related]
20. Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus.
Park JW; Jo WH
Eur J Med Chem; 2010 Feb; 45(2):536-41. PubMed ID: 19914748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
